Top Markets
Coin of the day
Guobang Pharma Ltd. Guobang Pharma Ltd.

Guobang Pharma Ltd.

605507
Rank in Stocks #7080
Guobang Pharma Ltd., a Chinese company, specializes in the research,... Guobang Pharma Ltd., a Chinese company, specializes in the research, development, manufacturing, and distribution of pharmaceutical products for both human and veterinary use within China. For human healthcare, their offerings encompass active pharmaceutical ingredients (APIs), intermediate compounds related to these APIs, and finished dosage forms. In the animal health sector, they provide veterinary APIs, various additives, and prepared formulations. The company was founded in 1996 and has its headquarters situated in Xinchang, China.
Share Price
$2.21
Market Cap
$1.73B
Change (1 day)
-0.65%
Change (1 year)
-4.69%
Country
CN
Trade Guobang Pharma Ltd. (605507)

Category

P/E ratio for Guobang Pharma Ltd. (605507)
P/E ratio as of 2026 TTM: 0
According to Guobang Pharma Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Guobang Pharma Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.